This Work Is Licensed under a Creative Commons Attribution 3.0 Unported License Combined Myc and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease
暂无分享,去创建一个
T. Jacques | D. Ellison | S. Robinson | R. Ruddle | F. Raynaud | D. Hargrave | S. Wharton | J. Boult | S. Bailey | J. Lindsey | S. Clifford | D. Williamson | K. Barker | L. Howell | F. Swartling | A. Hallsworth | L. Chesler | K. Petrie | B. Pizer | A. Michalski | S. Kuijper | S. Nicholson | S. Ryan | E. Schwalbe | E. Poon | Rebecca M Hill | C. Kwok | A. Joshi | Zai Ahmad | S. Crosier | K. Robson | Hill Rm | Kuijper S | Lindsey Jc | Petrie K | Schwalbe Ec | Barker K | Boult Jkr | Ahmad Z | Hallsworth A | Ryan Sl | Robinson Sp | Ruddle R | Raynaud Fi | Howell L Kwok | Joshi A | Nicholson Sl | Ellison Dw | Wharton Sb | Robson K | Michalski A | Hargrave D | Jacques Ts | Pizer B | Bailey S | Swartling Fj | Weiss Wa | Chesler L | Clifford Sc
[1] F. Speleman,et al. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. , 2014, Cancer letters.
[2] David T. W. Jones,et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Volker Hovestadt,et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.
[4] S. Keir,et al. Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.
[5] Paul A. Northcott,et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies , 2013, Acta Neuropathologica.
[6] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[7] T. Björk-Eriksson,et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[9] D. Ellison,et al. Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study. , 2011, European journal of cancer.
[10] A. Balmain,et al. Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.
[11] S. Vandenberg,et al. Pleiotropic role for MYCN in medulloblastoma. , 2010, Genes & development.
[12] M. Shago,et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Berthold,et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. , 2009, Neuro-oncology.
[14] Axel Benner,et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Clifford,et al. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials , 2009, British journal of neurosurgery.
[16] J. Mesirov,et al. Metagene projection for cross-platform, cross-species characterization of global transcriptional states , 2007, Proceedings of the National Academy of Sciences.
[17] D. Rowitch,et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. , 2006, Cancer research.
[18] A. Berns,et al. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. , 2006, Cancer research.
[19] Claire L Weston,et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Evan,et al. Temporal dissection of p53 function in vitro and in vivo , 2005, Nature Genetics.
[21] D. Ellison,et al. Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.
[22] W. Abdullah. Pediatr Blood Cancer , 2004 .
[23] R. Gilbertson,et al. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. , 2004, Brain research. Molecular brain research.
[24] P. Chène. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.
[25] T. Roderick,et al. FVB/N: an inbred mouse strain preferable for transgenic analyses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[26] E. Housepian,et al. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. , 1969, Radiology.
[27] S. Pfister,et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma , 2011, Acta Neuropathologica.